Becker's Healthcare December 7, 2022
Noah Schwartz

Syndax, a biopharmaceutical company focusing on cancer therapies, has announced the pricing of a $150 million public offering of common stock.

The offering price is $22 for each share of 6,818,182 shares of stock. Additionally, the company...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Investments, Pharma, Pharma / Biotech, Trends
11 drugs now in shortage
AbbVie tries to reassure investors on Humira biosimilar threat
FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder
This Biotech Startup Aims To Speed Up Drug Testing On Animals
Scientists reveal new method that could reduce waste from drug manufacturing

Share This Article